An exploratory analysis suggests a transfusion-transmissible agent associated with brain amyloidosis may be associated with some types of spontaneous intracerebral hemorrhage.
In a recent study, researchers found that low dose aspirin did not significantly reduce stroke risk in older adults, but increased the risk of intracranial bleeding or brain hemorrhage by 38%.
but experts say this is progress and perhaps just the beginning of hopefully even better treatments that may come along in the future. of course there are side effects to think about with both. they work by clearing the amyloid plaque buildups in the brain and that does come have side effects, specifically brain bleeding and brain swelling. and that was seen in the trial more than 20% of patients experienced this. most of that the company says was mild to moderate, but there were three patient deaths attributed to that side effect. so these are conversations that patients and doctors will have to have about the risks and benefits of the medicines. but they say it is a promising time. and in separate data coming out around the same conference, we are learning about where alzheimer s is most prevalent in the united states and that is estimated to be in east and southeast. this is the first study looking
alzheimer s. it is not boo to be used for people with severe or moderate alzheimer s. it s for people with early on set alzheimer s, early in the course of their illness. and also this medication has a lot of side effects including brain bleeding and brain swelling. 13% of patients in the trial actually got brain bleeding and swelling. and patients need frequent mri scans of their brains to look for brain bleeding or swelling. i think a lot of patients are not going to be interested in this medication at this time, but i think it ll be a good option for some, and i m really glad to be able to provide patients and caregivers this option. and i have to go, but, doctor, last week you published a column in the washington post about a health scare that you got that got you to slow down and re-prioritize your health and well-being. and i want to say as someone who s spoken with you so many times over the years especially during the pandemic, i m so glad
patients receiving the drug in its trial had brain swelling. 17% had brain bleeding, compared with 9% in the placebo group. the drug is administered through iv infusion once every two weeks. infusion centers are gearing up for an expected surge in new patients. in certain areas i anticipate we will receive at least 15 to 20% more patient referrals for this drug. reporter: joe is hoping he ll get more time with his wife and sons. any paintrents hopes to see m get married and have a family. i just want to experience what most people take for granted. the alzheimer s association said in a statement thursday that it welcomes the fda s full approval. the president and creo wrote,